Serum Immunologic Markers for Monitoring Allergen-Specific Immunotherapy

Immunology and Allergy Clinics of North America

Volumn 31, Issue 2, 2011, Pages 311-323

  Shamji, Mohamed H ^a   James, Louisa K ^a   Durham, Stephen R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Allergen immunotherapy; IgE blocking factor; IgE facilitated allergen binding; IgE mediated allergy; IgG4

Indexed keywords

ALUTARD; CD23 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; GRASS POLLEN EXTRACT; HLA DR ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOMODULATING AGENT; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO; RECOMBINANT ALLERGEN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLERGEN IMMUNOTHERAPY; ALLERGENICITY; ALLERGIC RHINITIS; ALLERGY; BASOPHIL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; EOSINOPHIL COUNT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REGULATORY T LYMPHOCYTE; REVIEW; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE ACTIVATION; TH2 CELL;

ALLERGENS; ANTIGEN PRESENTATION; BIOLOGICAL MARKERS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN ISOTYPES;

EID: 79955441842     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2011.03.005     Document Type: Review

References (57)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, i:1572-1573.
2. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102(4 Pt 1):558-562.
3. Durham S.R., Walker S.M., Varga E.M., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341(7):468-475.
4. Bonifazi F., Jutel M., Bilo B.M., et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005, 60(12):1459.
5. Durham S.R., Emminger W., Kapp A., et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010, 125(1):131-138.
6. Frew A.J., Powell R.J., Corrigan C.J., et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117(2):319-325.
7. Francis J.N., James L.K., Paraskevopoulos G., et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008, 121(5):1120-1125.
8. Haugaard L., Dahl R., Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993, 91(3):709-722.
9. Hunt K.J., Valentine M.D., Sobotka A.K., et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978, 299(4):157-161.
10. Varney V.A., Edwards J., Tabbah K., et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997, 27(8):860-867.
11. Wilson A.M., Sims E.J., Orr L.C., et al. An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. Br J Clin Pharmacol 2003, 55(4):354-359.
12. Golden D.B., Kagey-Sobotka A., Norman P.S., et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004, 351(7):668-674.
13. Lockey R.F. ARIA: global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001, 108(4):497-499.
14. James L.K., Shamji M.H., Walker S.M., et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011, 127(2):509-516.
15. Scadding G.W., Shamji M.H., Jacobson M.R., et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010, 40(4):598-606.
16. O'Hehir R.E., Gardner L.M., de Leon M.P., et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009, 180(10):936-947.
17. Passalacqua G., Albano M., Riccio A., et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999, 104(5):964-968.
18. Till S.J., Francis J.N., Nouri-Aria K., et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004, 113(6):1025-1034. [quiz: 1035].
19. Ippoliti F., De Santis W., Volterrani A., et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003, 14(3):216-221.
20. Bahceciler N.N., Arikan C., Taylor A., et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005, 136(3):287-294.
21. Jutel M., Akdis M., Budak F., et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003, 33(5):1205-1214.
22. Francis J.N., Till S.J., Durham S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003, 111(6):1255-1261.
23. Akdis C.A., Blesken T., Akdis M., et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998, 102(1):98-106.
24. Ling E.M., Smith T., Nguyen X.D., et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004, 363(9409):608-615.
25. van Neerven R.J., Wikborg T., Lund G., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999, 163(5):2944-2952.
26. Mobs C., Slotosch C., Loffler H., et al. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010, 184(4):2194-2203.
27. Radulovic S., Jacobson M.R., Durham S.R., et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008, 121(6):1467-1472.
28. Pilette C., Nouri-Aria K.T., Jacobson M.R., et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007, 178(7):4658-4666.
29. Chawes B.L., Edwards M.J., Shamji B., et al. A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid. J Allergy Clin Immunol 2010, 125(6):1387-1389.
30. Grindebacke H., Larsson P., Wing K., et al. Specific immunotherapy to birch allergen does not enhance suppression of Th2 cells by CD4(+)CD25(+) regulatory T cells during pollen season. J Clin Immunol 2009, 29(6):752-760.
31. Lichtenstein L.M., Ishizaka K., Norman P.S., et al. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973, 52(2):472-482.
32. Gleich G.J., Zimmermann E.M., Henderson L.L., et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982, 70(4):261-271.
33. Moverare R., Elfman L., Vesterinen E., et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002, 57(5):423-430.
34. Di Lorenzo G., Mansueto P., Pacor M.L., et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009, 123(5):1103-1110.
35. Gehlar K., Schlaak M., Becker W.-M., et al. Monitoring allergen Im- munotherapy of pollen-allergic patients: the ration of allergen-specificIgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999, 29:497-506.
36. Moverare R., Vesterinen E., Metso T., et al. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol 2001, 86(3):337-342.
37. Devey M.E., Wilson D.V., Wheeler A.W. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization. Clin Allergy 1976, 6(3):227-236.
38. Garcia B.E., Sanz M.L., Dieguez I., et al. Modifications in IgG subclasses in the course of immunotherapy with grass pollen. J Investig Allergol Clin Immunol 1993, 3(1):19-25.
39. Wachholz P.A., Soni N.K., Till S.J., et al. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003, 112(5):915-922.
40. Pirron U., Schlunck T., Prinz J.C., et al. IgE-dependent antigen focusing by human B lymphocytes is mediated by the low-affinity receptor for IgE. Eur J Immunol 1990, 20(7):1547-1551.
41. Santamaria L.F., Bheekha R., van Reijsen F.C., et al. Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells. Hum Immunol 1993, 37(1):23-30.
42. Karagiannis S.N., Warrack J.K., Jennings K.H., et al. Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells. Immunology 2001, 103(3):319-331.
43. Kehry M.R., Yamashita L.C. Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc Natl Acad Sci U S A 1989, 86(19):7556-7560.
44. van der Heijden F.L., Joost van Neerven R.J., van Katwijk M., et al. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993, 150(8 Pt 1):3643-3650.
45. Wurtzen P.A., Lund G., Lund K., et al. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008, 38(8):1290-1301.
46. Cooke R.A., Bernhard J.H., Hebald S., et al. Serological evidence of immunity with coexisting sensitization in hay fever type of human allergy. J Exp Med 1935, 62:733-751.
47. Lichtenstein L.M., Norman P.S., Winkenwerder W.L. Antibody response following immunotherapy in ragweed hay fever: Allpyral vs. whole ragweed extract. J Allergy 1968, 41(1):49-57.
48. Platts-Mills T.A., von Maur R.K., Ishizaka K., et al. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976, 57(4):1041-1050.
49. Aalberse R.C., van der Gaag R., van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983, 130(2):722-726.
50. van der Zee J.S., van Swieten P., Aalberse R.C. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 1986, 137(11):3566-3571.
51. Aalberse R.C., Schuurman J. IgG4 breaking the rules. Immunology 2002, 105(1):9-19.
52. Nouri-Aria K.T., Wachholz P.A., Francis J.N., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004, 172(5):3252-3259.
53. Shamji M.H., Wilcock L.K., Wachholz P.A., et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006, 317(1-2):71-79.
54. Shamji M., Ljørring C., Francis J.N., et al. Blocking antibodies: relationship between IgG4-associated inhibitory activity and clinical response to grass-pollen immunotherapy. J Allergy Clin Immunol 2010, 125(2 Suppl 1):AB131.
55. Petersen A.B., Gudmann P., Milvang-Gronager P., et al. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem 2004, 37(10):882-892.
56. Nelson H.S., Nolte H., Creticos P., et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011, 127(1):72-80.
57. Russell M.W., Mansa B. Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA. Scand J Immunol 1989, 30(2):175-183.